Abstract

Presented at the Midyear Clinical Meeting.

This evaluation found that appropriate use of fidaxomicin improved after addition to formulary with use restrictions, along with a decrease in 30-day CDI recurrence.

Document Type

Poster

Publication Date

2025

Share

COinS